Bharat Immunologicals & Biologicals Corporation Limited (BOM:524663)
India · Delayed Price · Currency is INR 21.41
-0.22 (-1.02%)
At close: Aug 8, 2025
BOM:524663 Revenue
Bharat Immunologicals & Biologicals Corporation had revenue of 76.50M INR in the twelve months ending September 30, 2023, down -89.99% year-over-year. In the fiscal year ending March 31, 2023, Bharat Immunologicals & Biologicals Corporation had annual revenue of 446.09M, down -43.09%.
Revenue (ttm)
76.50M
Revenue Growth
-89.99%
P/S Ratio
12.15
Revenue / Employee
n/a
Employees
n/a
Market Cap
929.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2023 | 446.09M | -337.79M | -43.09% |
| Mar 31, 2022 | 783.88M | -69.46M | -8.14% |
| Mar 31, 2021 | 853.34M | 184.97M | 27.68% |
| Mar 31, 2020 | 668.37M | -168.09M | -20.10% |
| Mar 31, 2019 | 836.46M | 488.47M | 140.37% |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 639.28B |